Acute myeloid leukemia in a chronic lymphocytic leukemia patient: diagnostic challenge (clinical case).

Abstract

Chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) coexistence in the same patient has been rarely reported, more frequently due to treatment with chemotherapeutic agents. Blood parameter changes in cancer patients may be interpreted as disease progression or iatrogenic effects related to aggressive treatment, leading to delayed diagnosis. In our article, we call attention to the possibility of AML development in CLL patients and its diagnostic challenge.

Keywords

chronic lymphocytic leukemia / acute myeloid leukemia / hematology analyzers / flags / peripheral blood smear / smudge cells / blasts

References

[1] Giri S, Bhatt VR, Khanal S, et al. Treatment-related acute myeloid leukemia in a chronic lymphocytic leukemia patient: role of fludarabine? Therapeutic Advances in Hematology. 2015;6(2):88-92. doi:10. 1177/2040620714566567

[2] Giri S., Bhatt V.R., Khanal S., et al. Treatment-related acute myeloid leukemia in a chronic lymphocytic leukemia patient: role of fludarabine? // Therapeutic Advances in Hematology. 2015. Vol. 6, №2. P. 88-92. doi:10.1177/204062071 4566567

[3] Al Mussaed E, Osman H, Elyamany G. Simultaneous existence of acute myeloid leukemia and chronic lymphocytic leukemia: a case report. BMC Cancer. 2016;16(1):739. doi:10.1186/s12885-016-2780-5

[4] Al Mussaed E., Osman H., Elyamany G. Simultaneous existence of acute myeloid leukemia and chronic lymphocytic leukemia: a case report // BMC Cancer. 2016. Vol. 16, №1. P. 739. doi:10.1186/s12885-016-2780-5

[5] Dong Q, Xiu Y, Bossler A, et al. CLL dedifferentiation to clonally related myeloid cells. Blood Advances. 2020;4(24):6169-74. doi:10.1182/blood advances.2020002726

[6] Dong Q., Xiu Y., Bossler A., et al. CLL dedifferentiation to clonally related myeloid cells // Blood Advances. 2020. Vol. 4, №24. P. 6169-6174. doi:10. 1182/bloodadvances.2020002726

[7] Schoorl M, Schoorl M, Chevallier M, et al. Flagging performance of the Sysmex XN2000 haematology analyser. International Journal of Laboratory Hematology. 2016;38(2):160-6. doi:10.1111/ ijlh.12461

[8] Schoorl M., Schoorl M., Chevallier M., et al. Flagging performance of the Sysmex XN2000 haemato-logy analyser // International Journal of Laboratory Hematology. 2016. Vol. 38, №2. P. 160-166. doi:10.1111/ijlh.12461

[9] Furundarena JR, Sainz M, Uranga A, et al. Comparison of abnormal cell flagging of the hematology analyzers Sysmex XN and Sysmex XE-5000 in oncohematologic patients. International Journal of Laboratory Hematology. 2017;39(1):58-67. doi:10. 1111/ijlh.12575

[10] Furundarena J.R., Sainz M., Uranga A., et al. Comparison of abnormal cell flagging of the hematology analyzers Sysmex XN and Sysmex XE-5000 in oncohematologic patients // International Journal of Laboratory Hematology. 2017. Vol. 39, №1. P. 58-67. doi:10.1111/ijlh.12575

[11] Eilertsen H, Saether PC, Henriksson CE, et al. Evaluation of the detection of blasts by Sysmex hematology instruments, CellaVision DM96, and manual microscopy using flow cytometry as the confirmatory method. International Journal of Laboratory Hematology. 2019;41(3):338-44. doi:10.1111/ijlh.12980

[12] Eilertsen H., Saether P.C., Henriksson C.E., et al. Evaluation of the detection of blasts by Sysmex hematology instruments, CellaVision DM96, and manual microscopy using flow cytometry as the confirmatory method // International Journal of Laboratory Hematology. 2019. Vol. 41, №3. P. 338-344. doi:10. 1111/ijlh.12980

RIGHTS & PERMISSIONS

Fernandes M., Martins J., Campos M., Magalhães C., Eremina Y.O.